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ABSTRACT
CK9 is a rainbow trout (Oncorhynchus mykiss) CC chemokine phylogenetically 
related to mammalian CCL25. Although CK9 is known to be transcriptionally regulated 
in response to inflammation particularly in mucosal tissues, its functionality has never 
been revealed. In the current work, we have demonstrated that CK9 is chemoattractant 
for antigen presenting cells (APCs) expressing major histocompatibility complex class 
II (MHC II) on the cell surface. Among these APCs, CK9 has a strong chemotactic 
capacity for both B cells (IgM+ and IgT+) and macrophages. Along with its chemotactic 
capacities, CK9 modulated the MHC II turnover of B lymphocytes and up-regulated 
the phagocytic capacity of both IgM+ cells and macrophages. Although CK9 had 
no lymphoproliferative effects, it increased the survival of IgT+ lymphocytes. 
Furthermore, we have established that the chemoattractant capacity of CK9 is strongly 
increased after pre-incubation of leukocytes with a T-independent antigen, whereas 
B cell receptor (BCR) cross-linking strongly abrogated their capacity to migrate to 
CK9, indicating that CK9 preferentially attracts B cells at the steady state or under 
BCR-independent stimulation. These results point to CK9 being a key regulator of B 
lymphocyte trafficking in rainbow trout, able to modulate innate functions of teleost 
B lymphocytes and macrophages.
INTRODUCTION
Chemokines or chemotactic cytokines are a family 
of cytokines that regulate immune cell migration under 
both inflammatory and normal physiological conditions. 
Constitutively expressed chemokines regulate homing, 
maturation and even microenvironmental segregation 
of immune cells within lymphoid organs, whereas, in 
response to inflammation, chemokines attract immune 
cells and modulate the activity of the recruited cells, thus 
conditioning the first steps of the immune response [1 , 2]. 
Chemokines are defined by the presence of four conserved 
cysteine residues and are divided into four subfamilies 
based on the distinctive pattern of the two N terminal 
cysteines: CXC (α), CC (β), C and CX3C classes [3]. 
Chemokines are rapidly changing proteins and 
evolve more quickly than most other immune genes, a 
reflection of different infectious experiences of the host 
[4, 5]. In addition, the level of diversity of CC chemokines 
seems high in fish relative to mammals, making one-
to-one orthologous relationships difficult to establish 
between mammalian and fish CC chemokines. In 2007, 
Peatman and Liu established seven large groups of fish 
CC chemokines through an extensive phylogenetic 
analysis using CC chemokine sequences from rainbow 
trout (Oncorhynchus mykiss), Atlantic salmon (Salmo 
salar), channel catfish (Ictalurus punctatus) and zebrafish 
(Danio rerio) along with mammalian CC chemokines 
[5]. These groups were named based on their mammalian 
membership as the CCL19/21/25 group, the CCL20 
Oncotarget17548www.impactjournals.com/oncotarget
group, the CCL27/28 group, the CCL17/22 group, the 
macrophage inflammatory protein (MIP) group, the 
monocyte chemotactic protein (MCP) group and a fish-
specific group. Among these, the CCL19/21/25 group 
is one of three groups showing higher evolutionary 
conservation between teleost fish and mammalian CC 
chemokines; however, the authors observed that most 
fish genes in this group were most closely related to 
CCL25, with lower similarity to CCL21. The branching 
pattern indicated that ancient vertebrates had multiple 
CCL25/21-like genes before the diversification of teleost 
fish species, however, recent phylogenetic analyses 
suggest that teleost fish may lack true CCL21 orthologues 
[6]. In some fish species, such as zebrafish, two genes 
that seem true orthologues of CCL25 are present [7]. On 
the other hand, the CCL19 subclade in the CCL19/21/25 
group is particularly well established and constitutes an 
independent gene [5]. 
In rainbow trout, after the designation of the first CC 
chemokine identified as CK1 [8] this nomenclature was 
maintained for subsequently discovered CC chemokine 
genes, bringing up the total number of CC chemokines to 
eighteen [9, 10]. Among them, CK9 is a CC chemokine 
ascribed within the CCL19/21/25 group, closely related 
to mammalian and zebrafish CCL25 [5]. This designation 
was later confirmed in an independent phylogenetic 
analysis [11]. Thus far, although multiple studies have 
been undertaken addressing the transcriptional regulation 
of CK9 in response to diverse stimuli and throughout 
different tissues, pointing to a preferential mucosal role 
[12-14], its biological activity has never been determined. 
In mammals, CCL25 signals exclusively through 
CCR9 [15] which is mainly expressed in the thymus 
where it regulates the trafficking of developing T cells 
[16] and in the intestine where it recruits T cells to Peyer´s 
patches [15, 17]. Interestingly, CCL25 is also chemotactic 
for IgA antibody secreting cells (ASCs), while IgM or 
IgG ASCs respond poorly [18, 19]. Similarly, Toll like 
receptor 2 (TLR2) ligands have been shown to induce IgA 
and CCR9 expression in circulating B lymphocytes [20], 
and during the course of an acute rotavirus infection both 
IgA and IgM ASCs express CCR9 and are able to migrate 
to CCL25 [21]. Likewise, mucosal immunization against 
Salmonella provokes a robust migration of specific IgA- 
and IgM-ASCs towards CCL25 [22]. CCL25 also has 
chemotactic potential towards activated macrophages [23] 
and CCR9+ macrophages are known to play a prominent 
role in acute liver inflammation [24] and rheumatoid 
arthritis [25]. Interestingly, it has recently been shown 
that only human M1 macrophages (classically activated 
macrophages) express CCR9 and migrate towards 
CCL25, while M2 macrophages (alternatively activated 
macrophages) do not have this ability [26].
In teleost fish, different B lymphocyte subsets can 
be found that are defined by their expression of the three 
immunoglobulin (Ig) isotypes present in fish. IgD+IgM+ 
B cells are present in all teleost species analyzed thus far 
and represent the majority of B lymphocytes in fish [27]. 
IgD+IgM- B cells have been reported in channel catfish 
[28] and in rainbow trout gills [29], but their role in 
immunity has not been clarified yet. Finally, a lineage of B 
cells uniquely expressing IgT/Z has been reported in some 
species [30, 31], where they seem particularly important 
for mucosal responses [31, 32]. 
In the current work, we have studied the biological 
activity of rainbow trout CK9, characterizing the specific 
cell types that are attracted to this chemokine, and then 
determined the bioactivity of CK9 on the recruited cells. 
Our results show that CK9 is a chemoattractant for antigen 
presenting cells (APCs), including B lymphocytes (both 
IgM+ and IgT+ B cells) as well as macrophages. CK9 
regulated the phagocytic capacity of both macrophages 
and IgM+ cells, and increased the major histocompatibility 
complex class II (MHC II) molecule turnover in both 
B lymphocyte subsets. Unlike other mammalian 
chemokines, CK9 did not show lymphoproliferative 
effects, but specifically increased the survival of IgT+ 
lymphocytes. Interestingly, the chemoattractant capacity 
of CK9 was significantly increased when leukocytes 
were pre-incubated with a T-independent antigen such 
as TNP-LPS but to a lesser extent when a T-dependent 
antigen was used. On the other hand, B cell receptor 
(BCR) cross-linking drastically reduced the capacity of 
B lymphocytes, especially IgM+ cells, to migrate to CK9. 
Our results suggest that CK9 is an ancient chemokine that 
regulates the innate functions of teleost B lymphocytes and 
macrophages, and suggests that rainbow trout CK9 and its 
homologues in other fish species are key modulators of B 
lymphocyte trafficking in teleost fish. 
RESULTS
CK9 attracts and activates RTS11 rainbow trout 
macrophages
Recombinant CK9 was produced in order to study 
its bioactivity. A protein of the expected size of 9.61 kDa 
was induced by IPTG stimulation of transformed BL21 
cells, purified under denaturing conditions, refolded 
in vitro and re-purified under native conditions. The 
recombinant CK9, when added to RTS11 cells at up to 
1000 ng/ml, had no effects on the expression of interleukin 
1β (IL-1β) and tumor necrosis factor α (TNF-α), which are 
known to be up-regulated by liposaccharide (LPS) in this 
system [33, 34], confirming that LPS contamination in the 
recombinant preparations was negligible [35].
The chemotactic activity of recombinant CK9 
was first tested on the rainbow trout macrophage cell 
line RTS11. Using transwell migration chamber assays, 
we analyzed the effect of different doses of CK9 on the 
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migratory capacity of RTS11 macrophages towards this 
chemokine and observed that CK9 attracted unstimulated 
trout macrophages in a dose-dependent manner, reaching 
very high significant levels of chemotaxis at 100 ng/
ml CK9 (Figure 1A). When CK10, another chemokine 
produced in parallel under the same conditions was tested 
using the same doses, no RTS11 cell migration was ever 
observed. Since chemokines not only recruit immune 
cells to sites of inflammation, but also have the capacity to 
activate the recruited cells [36], we investigated whether 
CK9 had an impact on the phagocytic response of RTS11 
macrophages. After incubation with 1 µm polystyrene-
based fluorescent beads for 3 h, RTS11 macrophages 
showed a modest phagocytic capacity (an average of 
9% of cells), which was dramatically increased by the 
presence of CK9 during the incubation, leading to an 
average of 41% of cells being phagocytic (Figure 1B). 
CK9 not only increased the number of phagocytic cells 
but also their capability to internalize beads, since the 
median fluorescence intensity (MFI) increased from 201.6 
(control) to 346.8 (CK9) (Figure 1B, bar plots). A hallmark 
of activated phagocytes is the generation of reactive 
oxygen species during the phagocytosis-associated 
respiratory burst [37], so we also analyzed the impact 
of CK9 on the respiratory burst activity of RTS11 cells. 
Interestingly, CK9 significantly induced respiratory burst 
activity in rainbow trout macrophages, to levels almost 
comparable to those obtained when RTS11 macrophages 
where incubated with the inducer PMA (Figure 1C). 
Furthermore, SOD significantly reduced the respiratory 
burst induced by either PMA or CK9, indicating specificity 
for both. Altogether, these data indicate that CK9 attracts 
trout macrophages and activates their phagocytic and 
microbicidal abilities.
CK9 attracts B cells from spleen, head kidney and 
blood as well as myeloid cells from head kidney
We next characterized the chemotactic activity 
of CK9 on rainbow trout unstimulated leukocytes from 
spleen, head kidney and peripheral blood (PBLs) using 
different CK9 doses. CK9 was a chemoattractant for 
trout leukocytes from spleen, head kidney and peripheral 
blood (Figure 2). The effect was dose-dependent, reaching 
significant levels of chemotaxis already with 10 ng/
ml in the case of kidney, and with 100 ng/ml of CK9 in 
all tissues analyzed (Figure 2B). Among the leukocytes 
attracted, a lymphocyte-like population (based on its 
SSC/FSC profile) was present in all tissues (Figure 2A, L 
population), whereas, interestingly, a migrated population 
of larger cells on the granulocyte-macrophage gate was 
also visible in head kidney leukocyte cultures (Figure 
2A, G-M population), an organ where these cell types are 
abundant. When CK10, another chemokine produced in 
parallel under the same conditions was tested using the 
same doses, no cell migration was ever observed in any of 
the tissues tested. 
Chemokines signal through G-coupled chemokine 
receptors which are specifically blocked by pertussis 
toxin (PTX), thus we also studied whether CK9-induced 
migration could be blocked by the pre-incubation of 
leukocytes with PTX. We found that pre-incubation of 
splenocytes with PTX prior to the chemotaxis assay had 
no effect on leukocyte viability but significantly blocked 
the migration to CK9 in a dose-dependent fashion (Figure 
S1), demonstrating that CK9 signals through a G-coupled 
receptor. 
Subsequently, to characterize the nature of the 
attracted cells, we performed a chemotaxis assay using 
a single CK9 dose (100 ng/ml), and then incubated the 
migrated cells with specific antibodies against IgM, 
IgT, CD8α and MHC II. Within the lymphoid gate, the 
chemokine mainly attracted MHC II+ B cells in leukocyte 
cultures from either spleen, head kidney or blood, 
accounting for an average of 74-92% of the migrated 
cells within the lymphoid gate (Figure 3), revealing that 
CK9 is a strong chemoattractant for APCs. Surprisingly, 
only an average of 42% of the cells attracted to CK9 in 
the kidney that fall within the myeloid gate are MHC-
II+ (Figure 3), thus the nature of the remaining cell types 
attracted remains unknown given the current availability 
of antibodies against trout leukocyte populations. Since 
APCs include macrophages, dendritic cells (DCs) and B 
cells, we also stained the migrated cells with anti-IgM and 
anti-IgT to study if B cells were attracted by CK9. Both 
IgM+ and IgT+ cells were among the main attracted cell 
types in spleen and blood, since together they accounted 
for an average of 64% and 69% of the attracted cells 
respectively (Figure 3). In contrast, the percentage of IgM+ 
and IgT+ cells in the attracted population from kidney was 
lower, suggesting that in this organ, other APCs different 
than B cells are also strongly attracted towards CK9. 
Finally, the levels of CD8α+ cells detected in the migrated 
cells was quite low (Figure 3), however, it is true that the 
percentage of CD8α+ cells was also quite low in leukocyte 
suspensions from these tissues, as previously reported 
[38]. Thus, our results reveal that CK9 is a common 
chemoattractant for different types of APCs, which in the 
case of B cell-rich tissues such as spleen or blood, mainly 
account for IgM+ and IgT+ lymphocytes. 
CK9 increases the phagocytic activity of naïve 
IgM+ B cells
Since rainbow trout IgM+ and IgT+ B cells have 
a potent phagocytic activity [31, 39], we wanted to 
determine if CK9 could also modulate this activity, as 
in the case of RTS11 cells. To carry out this experiment, 
PBLs were incubated with 1 µm polystyrene-based 
fluorescent beads for 3 h in the presence or absence of 100 
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Figure 1: Effect of CK9 on rainbow trout RTS11 macrophages. A. Chemotaxis assay in which different CK9 doses were 
introduced in the bottom wells of transwell chambers, whereas RTS11 cells were dispensed into the upper wells. After 2 h of incubation 
at 20ºC, the number of cells that had migrated to the bottom of the wells was quantified by flow cytometry. Average numbers of migrating 
cells are shown. B. RTS11 cells were incubated with Crimson Red fluorescent beads at a ratio of 1:10 (cell:beads) for 3 h in the presence 
or absence of CK9 (100 ng/ ml). The cells were then analyzed by flow cytometry to measure the fluorescence of internalized beads, as 
shown in the representative histograms. Solid grey overlays represent controls with no beads. Percentages of cells containing beads were 
determined and average percentage of phagocytic cells was calculated, as well as median fluorescence intensity (MFI) of the internalized 
beads. C. RTS11 cells were incubated with NBT (1 mg/ ml) in combination with either PMA (1 µg/ml) or CK9 (100 ng/ml). SOD (300 units/
ml) was included in some wells to verify the specificity of the reaction. After 30 min of incubation at 20ºC, NBT reduction was measured 
as the optical density at 620 nm. Data are shown as average readings (n = 6 assays, mean + SD). Statistical analysis was performed in each 
case, where * means p ≤ 0.05 and *** means p ≤ 0.005.
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Figure 2: Chemotactic activity of CK9 on rainbow trout leukocyte populations. Different doses of CK9 were introduced into 
the bottom well of a transwell chamber, whereas leukocytes from blood, head kidney or spleen were dispensed into the upper wells. After 
2 h of incubation at 20ºC, the number of cells that had migrated towards CK9 was quantified by flow cytometry. A. Average numbers of 
migrating cells (n = 6 fish, mean ± SD). Statistical analysis was performed in each case, where * means p ≤ 0.05 and ** means p ≤ 0.01. B. 
Representative dot plots. L: Lymphoid gate, G-M: Granulocyte-Macrophage gate.
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Figure 3: Characterization of leukocyte populations attracted to CK9. A single dose of 100 ng/ml was introduced into the 
bottom well of a transwell chamber, whereas leukocyte populations from blood, head kidney or spleen were dispensed into the upper wells. 
After 2 h of incubation at 20ºC, the cells that had migrated to the bottom of the wells were harvested and stained with anti-IgM, anti-
IgT, anti-CD8α or anti-MHC II specific antibodies. A. Representative dot plots and staining patterns for each tissue are shown. B. Mean 
percentage of specific leukocyte populations in initial cultures and in CK9-attracted cells (n = 5).
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ng/ml CK9. Cells were then labelled with anti-IgM and 
anti-IgT mAbs, to determine the phagocytic capacity of 
each specific subpopulation. CK9 increased the number 
of phagocytic IgM+ B cells with very high statistical 
significance (Figure 4A), but had no effect on the number 
of phagocytic IgT+ B cells (Figure 4). As expected, CK9 
did not increase the MFI of IgT+ B cells, but surprisingly, 
also had no effect on IgM+ B cells (Figure 4B). Thus, it 
seems that CK9 is able to increase the number of IgM+ B 
cells that can phagocytose an average number of beads, 
but is not able to increase the capability of IgM+ B cells to 
ingest a higher bead number. 
CK9 activates the internalization of cell surface 
MHC II in resting B cells
Since CK9 was able to enhance the phagocytosis of 
extracellular particles by IgM+ cells, we additionally tested 
whether this chemokine influenced MHC II trafficking 
on both IgM+ and IgT+ B lymphocyte populations. After 
a 24 h exposure to CK9, both IgM+ and IgT+ peripheral 
blood B cells significantly downregulated their levels of 
surface MHC II (Figure 5A). A similar result was observed 
when splenic B cells were analyzed, since CK9 induced 
a very significant decrease of surface MHC II on IgT+ B 
cells, and, to a lesser extent, on IgM+ B cells (Figure 5B). 
Interestingly, total levels (intracellular plus extracellular) 
of MHC II were not affected by CK9 on either B cell 
Figure 4: Effect of CK9 on the phagocytic capacity of B lymphocytes. PBLs were incubated with Crimson Red fluorescent 
beads at a ratio of 1:10 (cell:beads) for 3 h in the presence or absence of CK9 (100 ng/ ml). A. Cells were stained with either anti-IgM or 
anti-IgT antibodies and then analyzed by flow cytometry, as shown in the representative histogram. B. Average percentages of phagocytic 
cells were also calculated (left bar plot) as well as median fluorescence intensities (MFI) (right bar plot) of the beads in order to determine 
the phagocytic capacity and the effects of CK9. Data are shown as mean ± SD (n = 7 fish). Statistical analysis was performed in each case, 
where *** means p ≤ 0.005.
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population from blood (Figure 5C) or spleen (Figure 5D). 
The fact that surface MHC II levels decrease on B cells 
while total levels remains the same demonstrates that 
CK9 activates MHC II trafficking from the membrane to 
intracellular compartments.
CK9 has no proliferative effects but increases the 
survival of IgT+ cells
Unlike other mammalian chemokines with 
lymphoproliferative effects on B cells [40], CK9 did not 
induce on its own the proliferation of IgM+ B cells (Figure 
6A, B) or IgT+ cells (data not shown). When blood B cells 
were exposed to TNP-LPS as a T-independent antigen and 
TNP-KLH as a T-dependent antigen [41], we observed that 
TNP-LPS was much more efficient in triggering a strong 
proliferative response of naïve IgM+ B lymphocytes than 
TNP-KLH (Figure 6A, 6B). However, the combination 
of CK9 together with TNP-LPS or TNP-KLH produced 
no significant modulation of the proliferative response to 
either of the two stimuli (Figure 6A, 6B). Surprisingly, 
neither TNP-LPS nor TNP-KLH were capable of inducing 
a proliferative response of blood or spleen IgT+ B 
lymphocytes (data not shown). 
Despite having no lymphoproliferative effects, 
CK9 significantly increased the survival of IgT+ B cells in 
both PBLs (Figure 6C) and splenocytes (Figure 6D) after 
4 days of culture. This effect is highly specific for this 
population, as it was not visualized for IgM+ cells. Given 
the transcriptional profile of CK9, these results strongly 
suggest that CK9 contributes to the maintenance of IgT+ 
B cell viability in the mucosal surfaces. 
The pre-stimulation of leukocytes modulates their 
migratory capacities towards CK9
We also studied whether the pre-stimulation of B 
lymphocytes altered their capacity to migrate towards 
CK9 using TNP-LPS and TNP-KLH antigens. In blood, 
only TNP-LPS significantly increased the capacity of 
leukocytes to migrate to CK9 (Figure 7A). In spleen, 
although both TNP-LPS and TNP-KLH gave increased 
numbers of migrated cells (Figure 7B), the effects of 
TNP-LPS were much stronger than those of TNP-KLH. 
Since TNP-LPS has strong lymphoproliferative effects, 
it was possible that the increased chemotaxis obtained 
in TNP-LPS-stimulated cultures was a consequence of 
an increased number of IgM+ cells. Thus, to rule out this 
confounding factor, we repeated this experiment, adjusting 
the number of cells not only prior to the 24 h stimulation 
with TNP-LPS, but again before the cells were introduced 
into the chemotaxis chambers. In these conditions, 
TNP-LPS-stimulated cells again showed a significantly 
increased migration towards CK9 with similar percentages 
of IgM+ and IgT+ cells (data not shown), supporting the 
statement that pre-stimulation of B lymphocytes by a 
T-independent antigen increases their responsiveness to 
CK9.
BCR engagement in IgM+ cells inhibits their 
capacity to migrate towards CK9
Contrary to the effects obtained by stimulation with 
a T-independent antigen, we observed that BCR cross-
linking with an anti-IgM antibody significantly suppressed 
the capacity of IgM+ cells to migrate towards CK9 both 
in blood (Figure 8A) and spleen (Figure 8B). BCR cross-
linking through anti-IgM is known to mimic a high 
affinity antigen, whereas TNP-LPS signals through low 
affinity membrane Igs and pattern recognition receptors 
which induce a much weaker stimulatory signal on B 
cells [42]. The effect of anti-IgM was visible when cells 
were incubated with the antibody for 24 h (Figure 8A, 
B) or even 5 min (Figure 8C, 8D), despite the fact that 
incubation with this antibody for these time periods had 
no effect on the cell viability of the cultures as determined 
by propidium iodide (data not shown). This IgM-mediated 
suppression was observed when the antibody was added 
alone or in combination with the anti-IgT antibody but not 
when the anti-IgT antibody was used on its own (Figure 
8A, 8B). The reason for this lack of effect in response 
to the anti-IgT antibody could be a result of lower 
percentages of IgT+ cells in the leukocyte cultures, or 
might be a consequence of a lower activating capacity for 
this antibody. Either way, the anti-IgT antibody provokes 
a weak calcium influx in blood leukocytes whereas the 
anti-IgM provoked a much stronger calcium influx 
(Figure 8E) that confirms BCR cross-linking and a strong 
B lymphocyte activation [43]. To unequivocally confirm 
that the inhibition of responsiveness to CK9 is due to B 
cell activation with the consequent calcium influx, we also 
incubated blood and spleen leukocytes with ionomycin 
for 5 min to provoke maximum intracellular calcium 
release. In this case, there was a complete blockage of the 
migratory capacities of leukocytes towards CK9 (Figure 
8C, 8D), confirming that when B lymphocytes are fully 
activated by a high affinity antigen (such as that mimicked 
by anti-IgM) they no longer migrate towards CK9. 
DISCUSSION
In the current study, we have established the 
chemoattractant potential of CK9, an ancient chemokine 
with close homology to mammalian CCL25, towards 
trout MHC II+ APCs, including B lymphocytes (both 
IgM+ and IgT+ B cells) and macrophages, and established 
its potential to regulate specific immune functions in the 
different recruited cell types. 
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Figure 5: Effect of CK9 on the expression of MHC II on trout B lymphocytes. Spleen and blood leukocytes were incubated 
with CK9 (100 ng/ml) or control media for 24 h at 20 ºC. After that time, MHC II cell surface expression on blood A. and spleen B.. IgM+ 
or IgT+ B cells was estimated by flow cytometry using a specific anti-MHC-II monoclonal antibody in combination with an anti-IgM or an 
anti-IgT antibody. In parallel, total MHC-II levels (intracellular plus extracellular) on blood C. and spleen D. B cells was estimated by flow 
cytometry using a specific anti-MHC II monoclonal antibody after fixation and permeabilization of previously stained IgM+ and IgT+ cells. 
Plots show MHC II expression in IgM+ or IgT+ cells from CK9-treated cultures (line) compared to MHC II expression in corresponding 
control cultures (grey plot, overlaid). Isotype control is represented by a dashed line. MHC II mean fluorescence intensity (MFI) was 
calculated for each sample and plotted. Data are shown as MFI ± SD (n = 6 fish). Statistical analysis was performed in each case, where * 
means p ≤ 0.05 and *** means p ≤ 0.005.
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Figure 6: Effect of CK9 on IgM+ and IgT+ B cell survival and proliferation. A. PBLs were incubated with TNP-LPS or TNP-
KLH (5 mg/ml) in the absence or presence of CK9 (100 ng/ml) for 3 days at 20 ºC. Controls without stimuli, with or without CK9, were 
also included. Bromodeoxyuridine (BrdU, 10 µM) was then added to the cultures and cells were incubated for an additional 24 h. After that 
time, trout cells were collected and stained with anti-IgM, then fixed, permeabilized and stained with an anti-BrdU antibody and analysed 
by flow cytometry. The histogram shows the percentage of proliferating IgM+ cells (BrdU+ / IgM+). Data are shown as mean % ± SD (n = 
5 fish). B. Representative flow cytometry charts are also shown. Survival of PBLs C. and splenocytes D. incubated with control medium 
or medium containing CK9 (100 ng/ml) was also determined after 4 days of culture at 20 ºC. After that time, cultures were stained with 
anti-IgM and anti-IgT antibodies to quantify survival of IgM+ and IgT+ B cells in the cultures. The number of cells in each culture was 
normalized to each control value, thus representing the effect of CK9 on survival as fold induction. Data are shown as mean ± SD (n = 5 
fish). Statistical analysis was performed in each case, where * means p ≤ 0.05 and *** means p ≤ 0.005.
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If we compare the CK9-attracted cell types to those 
recruited by CCL25 in mammals, significant differences 
are observed. While CK9 attracts unstimulated RTS11 
macrophages and kidney MHC II+ myeloid cells, CCL25 
has only been shown to attract previously activated 
macrophages [23-25]. In humans, CCL25 has also been 
shown to promote the differentiation of monocytes to 
macrophages [25] and likewise, we have observed an 
activation of macrophages in response to CK9, specifically 
on their phagocytic and respiratory burst activity, which 
should increase their antigen presenting and microbicidal 
potential. 
Concerning B lymphocytes, although CCL25 
exclusively attracts B lymphocytes that have differentiated 
towards ASCs [18-22], CK9 is a strong chemoattractant 
for naïve B lymphocytes in trout. Interestingly, B 
lymphocytes in teleost fish are known to produce large 
amounts of natural antibodies in physiological conditions 
[44] and are known to share many functions with 
mammalian B1 lymphocytes responsible for the secretion 
of natural antibodies in homeostasis [45], such as for 
example their phagocytic capacity [46, 47]. On the other 
hand, when the leukocyte cultures were stimulated with a 
T-independent antigen such as TNP-LPS, known to induce 
antibody secretion (data not shown), the capacity of B 
lymphocytes to migrate towards CK9 was significantly 
increased. This effect was only observed to a certain extent 
when a T-dependent antigen such as TNP-KLH was used, 
thus demonstrating that resting B lymphocytes are best 
activated for CK9 responsiveness under T-independent 
stimulation. Similarly, trout B lymphocytes strongly 
proliferated in response to TNP-LPS but not to TNP-KLH. 
All these results, suggest a great amount of functional 
similarities between mammalian B1 cells and teleost B 
lymphocytes and in consequence, it would be of interest 
to study if CCL25 is chemotactic for mammalian B1 
subpopulations as it is for ASCs.
Overall, our results point to a key role of this 
chemokine in the trafficking of B cells towards sites 
of inflammation during a pathogenic exposure. In this 
regard, previous transcriptional studies have revealed 
an up-regulation of CK9 in gills in response to a VHSV 
Figure 7: Effect of B lymphocyte stimulation on the migratory capacity of leukocytes towards CK9. Leukocyte populations 
from blood A. or spleen B. were incubated with TNP-LPS or TNP-KLH (5 mg/ml) or control medium, for 16 h at 20ºC. After that time, 
the cells were introduced into the upper wells of a transwell chamber, whereas 100 ng/ml CK9 were introduced into the bottom well of the 
chambers. After 2 h of incubation at 20ºC, the number of cells that had migrated to the bottom of the wells was quantified by flow cytometry. 
Data are shown as mean ± SD (n = 5 fish). Statistical analysis was performed in each case, where * means p ≤ 0.05 and *** means p ≤ 0.005.
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bath infection [13] and in the intestinal tract after oral 
vaccination or infection with infectious pancreatic 
necrosis virus (IPNV), a virus with marked tropism for 
the digestive system [14]. In contrast, CK9 mRNA levels 
were not modulated in spleen or head kidney when VHSV 
or IPNV were injected intraperitoneally [12], but were 
significantly increased locally after an intraperitoneal 
virus injection [48]. Although teleost IgT+ B cells are 
present in all immune tissues in physiological conditions, 
they have been shown to play an important role in 
mucosal immunity [31] in that the number of IgT+ cells in 
mucosal surfaces strongly increase in response to different 
pathogenic encounters [31, 32]. On the other hand, IgM+ 
B lymphocytes have also been shown to be recruited to 
mucosal sites upon antigenic exposure [49]. Furthermore, 
in contrast to what occurs in mammals, in teleost fish, B 
lymphocytes, and specially IgM+ cells, seem to be one 
of the main responders to inflammation, being directly 
mobilized to inflammation sites. For example, IgM+ B 
cells are known to be recruited to the peritoneum after a 
bacterial injection, representing around two thirds of the 
recruited cells after 48 h [50] and are one of the main 
cells that infiltrate the muscle after DNA vaccination [51]. 
Taken together, it seems that CK9 likely plays a key role 
in the mobilization of both IgM+ and IgT+ B lymphocytes 
from central immune organs to mucosal surfaces or sites of 
inflammation. The kidney is the main hematopoietic organ 
in fish and consequently contains a wider variability of 
Figure 8: Effect of BCR cross-linking on the migratory capacity of leukocytes towards CK9. Leukocyte populations from 
blood A. or spleen B. were incubated with 0.5 mg/ml of anti-IgM antibody, 0.5 mg/ml of anti-IgT antibody or a combination of both, for 24 
h at 14ºC. After that time, the cells were introduced into the upper wells of a transwell chamber, whereas 100 ng/ml CK9 were introduced 
into the bottom well of the chambers. After 2 h of incubation at 20ºC, the number of cells that had migrated to the bottom of the wells was 
quantified by flow cytometry. In parallel, leukocyte populations from blood C. or spleen D. were incubated with 0.5 mg/ml of anti-IgM or 
1 mM ionomycin for 5 min at 14ºC. After that time, the cells were introduced into the upper wells of a transwell chamber, whereas 100 ng/
ml CK9 were introduced into the bottom well of the chambers. After 2 h of incubation at 20ºC, the number of cells that had migrated to the 
bottom of the wells was quantified by flow cytometry. Average numbers of migrating cells (n = 5-7 fish, mean ± SD) are shown. Statistical 
analysis was performed in each case, where * means p ≤ 0.05, ** means p ≤ 0.01 and *** means p ≤ 0.005. E. PBLs were loaded with Fluo-
3 AM to follow the amount of intracellular calcium upon stimulation with 0.5 mg/ml of anti-IgM, 0.5 mg/ml of anti-IgT or 1mM ionomycin 
(positive control) by flow cytometry. Data are representative of five independent experiments.
Oncotarget17559www.impactjournals.com/oncotarget
leukocyte types, including different myeloid populations 
such as granulocytes and macrophages [52]. Accordingly, 
in this organ CK9 also attracts a large subpopulation 
of MHC II+ cells that are not B cells, possibly DCs or 
macrophages. These cells might also be recruited by CK9 
to the periphery, where, together with B cells, they can 
capture and present specific antigens.
Unlike other mammalian chemokines [40], CK9 
showed no lymphoproliferative effects on its own, nor was 
it capable of modulating the lymphoproliferative effects 
of other stimuli. Nevertheless, it produced a marked 
increase of IgT+ B lymphocyte survival that was not 
observed in the case of IgM+ B cells. This result indicates 
that although CK9 is able to attract both B lymphocyte 
subsets, the activation/ differentiation signals it provokes 
in the cells differ considerably and again points to an 
important mucosal role for this chemokine. Similarly, 
CK9 up-regulated the phagocytic capacity of IgM+ B 
cells by increasing the percentage of cells with phagocytic 
potential, but this effect was not observed in IgT+ B cells. 
Thus, it would be interesting to know if the CK9 receptor 
signaling in these two cell types is different. In the case 
that trout CCR9, as expected, is the receptor for CK9, it is 
interesting to note that two CCR9 molecules with marked 
differences in their transcriptional regulation have been 
reported in trout [53]. On the other hand, similar effects 
of CK9 were observed in both B lymphocyte subsets 
concerning the regulation of MHC II expression on the 
cell membrane. This CK9-induced downregulation of 
MHC II on the cell membrane seemed contradictory at 
first with the increased phagocytic capacity observed in 
IgM+ cells. Therefore, we decided to measure total MHC 
II protein levels in parallel, and found that total levels 
remained unaffected. It is known that in mammals, in 
contrast to other APCs, resting B cells accumulate most 
of the MHC II molecules at the cell surface and very 
little resides in endosomal compartments, whereas, upon 
activation, MHC II is redistributed to antigen processing 
compartments [54]. Given our results, it seems that 
CK9 activates the trafficking of MHC II molecules to 
endosomal compartments, which should increase antigen 
loading thus enhancing antigen presenting capacities. 
Finally, one of the most interesting results from 
our study was the fact that BCR cross-linking, induced 
by incubation with anti-IgM, reduced the migratory 
capacity of IgM+ B lymphocytes. In contrast to the 
stimulatory effects provoked by a T-independent antigen, 
BCR engagement significantly reduced the capacity of 
B cells to migrate towards CK9. As occurs in mammals, 
BCR cross-linking activates B lymphocytes, inducing 
intracellular calcium mobilization. Surprisingly, this 
blocking effect was not observed with anti-IgT, but this 
lack of response could be due to the lower numbers of 
IgT+ cells in these tissues and/or lower cross-linking 
potential of the antibody, which resulted in a rather weak 
intracellular calcium mobilization. This inhibition of B cell 
migration in response to antigen engagement has also been 
reported in mammals for chemokines such as CXCL12 
[55-57], a consequence of a marked decrease of CXCR4 
membrane expression upon stimulation [55-57] which is 
independent of calcium mobilization, but is mediated by 
protein kinase C (PKC) [56]. In contrast, the inhibition 
of CK9 responsiveness by BCR engagement was strongly 
dependent on calcium mobilization, as incubation with 
ionomycin completely blocked the migration in the 
cultures. 
In summary, the functional assays performed with 
CK9 reveal that this chemokine is a strong chemoattractant 
for both B lymphocytes and macrophages. Consequently, 
it regulates some of the shared functions between these 
cells types, such as their phagocytic capacity and their 
antigen presenting properties (through modulation of 
MHC II). Taking into account these results, as well as 
previous transcriptional data that points to a preferential 
induction of CK9 in mucosal sites, this chemokine is 
likely to play an important role in the mobilization of both 
IgM+ and IgT+ B cell subpopulations to mucosal sites, and 
the survival of IgT+ B lymphocytes at these sites. This 
capacity of B cells to migrate to CK9 was increased by 
a T-independent antigen exposure but was repressed by 
BCR-engagement, suggesting that once a B cell has found 
a high affinity cognate antigen, CK9 unresponsiveness 




Female rainbow trout (Oncorhynchus mykiss) adults 
of ∼100 g were obtained from Centro de Acuicultura El 
Molino (Madrid, Spain) and maintained at the animal 
facilities of the Centro de Investigación en Sanidad 
Animal in a recirculating water system at 16°C, with 12:12 
h light/dark photoperiod. Fish were fed twice a day with 
a commercial diet (Skretting). Prior to any experimental 
procedure, fish were acclimatized to laboratory conditions 
for at least 2 weeks. All of the experiments described 
comply with the Guidelines of the European Union 
Council (2010/63/EU) for the use of laboratory animals 
and have been approved by the Instituto Nacional de 
Investigación Agraria y Alimentaria (INIA) Ethics 
Committee. 
Production of recombinant CK9
The coding region of the predicted mature CK9 
peptide (Acc. Nos. BX316999 and BX855929) was 
amplified from a plasmid clone using primers (forward: 
CAAGGCTCTTATGGGAACTGCTGT and reverse: 
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GTTGCTTTGCTGCTTATCAACAACAGT) and the Q5 
high fidelity enzyme (New England Biolabs, UK). The 
amplified product was cloned to a pET vector (Invitrogen). 
The construct (pET-CK9) encodes an identical CK9 mature 
amino acid sequence with the addition of methionine at the 
N-terminus and a his-tag (GSGHHHHHHHH) added at the 
C-terminus for purification. Thus, the recombinant trout 
CK9 is 84 aa, with a calculated molecular weight of 9.61 
kDa and a theoretical pI of 9.79. Following transformation 
of the pET-CK9 plasmid into BL21 Star (DE3) competent 
cells (Invitrogen), the induction of recombinant protein 
production, purification under denaturing conditions, 
refolding, re-purification under native conditions, SDS-
PAGE analysis of proteins and quantification of protein 
concentration were as described previously [35, 58, 59]. 
The refolding buffer contained 50 mM Tris-HCl (pH7.5), 
10% glycerol, 0.6 M arginine monohydrochloride, 1 M 
3-(1-Pyridinio)-1-propanesulfonate (known as NDSB 
201 and PPS, Sigma), 0.2% PEG3350 and 5 mM 
2-mercaptoethanol. The purified protein was desalted in 
desalting buffer (DSB) (PBS containing 50% glycerol) 
using PD-10 Desalting Columns (GE Healthcare). After 
sterilization with a 0.2 µm filter, the rCK9 (0.6 mg/ml) 
was aliquoted and stored at -80oC ready for stimulation 
of cells.
Leukocyte isolation and cell lines
Rainbow trout were killed by MS-222 (Sigma) 
overdose and blood was extracted with a heparinized 
needle from the caudal vein and diluted 10 times with 
L-15 medium (Invitrogen) supplemented with 100 I.U./
ml penicillin plus 100 µg/ml streptomycin (P/S, Life 
Technologies), 10 units/ml heparin (Sigma) and 5% FCS 
(Life Technologies). Single cell suspensions from spleen 
and head kidney were obtained using 100 µm nylon 
cell strainers (BD Biosciences), placed onto 30/51% 
discontinuous Percoll (GE Healthcare) density gradients 
and centrifuged at 500 x g for 30 min at 4ºC. The cells 
at the interface were collected and washed twice in L-15 
containing 5% FCS. 
RTS11, a continuous rainbow trout macrophage-
like cell line, originally isolated from a long-term spleen 
hematopoietic culture [60] was maintained at 18ºC in L-15 
medium supplemented with P/S and 15% FCS. Cells were 
grown at a high cell density and passaged at a 1:2 ratio as 
described previously [60]. 
Flow cytometry
The anti-trout CD8α (mAb rat IgG, 7 μg/ml), the 
anti-trout MHC II β-chain [mAb mouse IgG1; used as an 
Allophycocyanin (APC) fluorescently-labelled version], 
the anti-trout IgM [1.14, mAb mouse IgG1; used as a 
Phycoerythrin (PE) fluorescently-labelled version] and 
the anti-trout IgT (mAb mouse IgG2a; used as a PE 
fluorescently-labelled version) used in this study have 
been previously characterized [31, 38, 61, 62]. Primary 
antibodies were conjugated by using Lightning-Link APC 
or Lightning-Link R-PE (Innova Biosciences). A mix of 
corresponding isotype control antibodies (BioLegend) 
was used in each experiment to rule out non-specific 
binding. For extracellular staining, isolated cells were 
incubated for 30 min with primary antibodies, washed 
twice with staining buffer (PBS containing 1% FCS and 
0.5% sodium azide) and stained for 20 min with secondary 
Ab for anti-CD8α detection [R-PE F(ab’)2 fragment 
of goat anti-rat IgG (H+L) (Life Technologies)] when 
needed. To determine total (intracellular and extracellular) 
MHC II levels, cells were fixed for 5 min with 4% 
paraformaldehyde in PBS, then permeabilized for 30 min 
in permeabilizitation buffer (staining buffer containing 
0.1% saponin). Then, the cells were incubated with MHC 
II-APC antibody in permeabilization buffer for another 
30 min. After incubation, cells were washed three times 
with staining buffer, and analyzed on a FACSCalibur flow 
cytometer (BD Biosciences) equipped with CellQuest Pro 
software. Flow cytometry analysis was performed with 
FlowJo 10 (TreeStar).
Chemotaxis assays
Chemotaxis was assessed using 3 μm (for primary 
cultures) or 5 μm (for RTS11 cells) pore polycarbonate 
Transwell chambers (Sigma), following the manufacturer´s 
instructions. Briefly, 600 µl of control medium (L-15 
medium supplemented with P/S and 5% FCS) or medium 
containing 1, 10 or 100 ng/ml recombinant CK9 were 
added to the bottom chambers. In the upper chambers, 
100 µl of RTS11 cells or primary cells (2 x 106 cells/ml) 
were dispensed. To test the specificity of the migration, 
in some experiments leukocytes were previously 
incubated with PTX (200 or 500 ng/ml) for 2 h, prior to 
conducting the chemotaxis assays. When needed, spleen 
or blood leukocytes were activated with TNP-LPS (5 
µg/ml) or TNP-KLH (Keyhole Limpet Hemocyanin) (5 
µg/ml) (Sigma) for 24 h at 20ºC before conducting the 
chemotaxis assays. In other experiments, primary cells 
were pre-stimulated with 0.5 mg/ml of anti-IgM antibody, 
0.5 mg/ml of anti-IgT antibody or a combination of both, 
for 24 h at 14ºC, or with 0.5 mg/ml of anti-IgM or 1 mM 
ionomycin for 5 min at 20ºC. Cells in migration chambers 
were incubated for 2 h at 20ºC, then the 600 µl of the 
bottom chamber were harvested and the migrated cells 
were analyzed based on side and forward light scatter 
(SSC/FSC) parameters on a FACSCalibur flow cytometer 
equipped with CellQuest sofware (BD Biosciences) at 
a constant flow time (1 min). In some experiments, the 
migrated cells were stained with mAbs against IgM, IgT, 
CD8α and MHC II or isotype control when needed and 
analyzed by flow cytometry.
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Respiratory burst activity
To analyze the respiratory burst activity of RTS11 
trout macrophages, we used the Nitro Blue Tetrazolium 
(NBT, Sigma) method. For this, cells were seeded in 
96-well plates (Nunc) at a concentration of 2 x 105 
cells per well, washed and resuspended in 1X Phenol 
Red-Free Hank´s Balanced Salt Solution (HBSS, Life 
Technologies). Then, NBT was added to the cells at a final 
concentration of 1 µg/ml, in the presence or absence of 
100 ng/ml CK9. As a positive inducer of the respiratory 
burst, 1 µg/ml of PMA (Sigma) was included in some 
wells. To assess the specificity of the reaction, 300 U/ml 
of Superoxide Dismutase (SOD, Sigma) was used in some 
wells in combination with either CK9 or PMA. Cells were 
incubated for 1 h at room temperature, in the dark, and 
then centrifuged. The supernatant was discarded and cells 
were incubated with absolute methanol for 5 min at room 
temperature. Methanol was then discarded and the cells 
were air-dried for 30 min. The reaction was developed by 
the addition of a developing buffer (120 μl of 2 M KOH 
and 140 μl of DMSO per well). Samples were incubated 
for 5 min and optical density at 620 nm measured, to 
determine reduction of the NBT substrate. 
Phagocytic activity
For the analysis of phagocytosis, leukocytes or 
RTS11 cells were seeded in 96-well plates (Nunc) at 
a cell density of 2x105 cells per well and incubated 
for 3 h at 20ºC with fluorescent beads (FluoSpheres® 
Microspheres, 1.0 µm, Crimson Red Fluorescent 625/645, 
2% solids; Life Technologies) at a cell:bead ratio of 1:10 
in the presence or absence of 100 ng/ml CK9. Cells were 
harvested using a standard cell scraper (Corning). Non-
ingested beads were removed by centrifugation (100 x g 
for 10 min at 4 ºC) over a cushion of 3% (weight/volume) 
BSA (Fraction V; Fisher Scientific) in PBS supplemented 
with 4.5% (weight/volume) D-glucose (Sigma). Cells were 
resuspended in staining buffer (PBS containing 1% FCS 
and 0.5% sodium azide), labelled with the flow cytometry 
antibodies when needed, and analyzed on a FACSCalibur 
flow cytometer.
Cell proliferation
A BrdU Flow kit (BD Biosciences) was used to 
measure the specific proliferation of IgM+ and IgT+ B 
cells, following the manufacturer’s instructions. Spleen or 
blood leukocytes at a concentration of 2 × 106 cells per ml 
were incubated for 3 days at 20°C in control medium or 
medium containing the different stimuli and/or CK9 (100 
ng/ml). As lymphoproliferative stimuli, TNP-LPS (5 µg/
ml) or TNP-KLH (5 µg/ml) were used. After this time, 
bromodeoxyuridine (BrdU) (10 μM) was added to the 
cultures, and cells were incubated for an additional 24 h. 
Trout cells were collected and stained with anti-IgM-PE 
or anti-IgT-PE MAbs and then fixed and permeabilized 
following the manufacturer’s instructions. In brief, cells 
were fixed with Cytofix/Cytoperm buffer for 15 min on 
ice, incubated with Cytoperm Permeabilization Buffer 
Plus for 10 min on ice and refixed with Cytofix/Cytoperm 
buffer during 5 min at room temperature. Cells were then 
incubated with DNase (30 μg/106 cells) for 1 h at 37°C 
to expose the incorporated BrdU. Finally, the cells were 
stained with FITC anti-BrdU mAb and analyzed by flow 
cytometry.
Calcium flux analysis
For calcium flux analysis, the calcium indicator 
Fluo-3 AM (Life Technologies) was used, following the 
manufacturer´s instructions. Briefly, Fluo-3 was dissolved 
in DMSO and further diluted in an equal volume of 20% 
(w/v) Pluronic F-127 (Life Technologies). Cells were 
incubated with Fluo-3 AM at a final concentration of 5 
µM, diluted in L-15 medium without FCS, for 60 min. 
After collecting and washing the cells with staining buffer, 
a baseline reading for 45 s was acquired by flow cytometry 
and then 0.5 µg/ml of anti-IgM, 0.5 µg/ml of anti-IgT or 
1 µM ionomycin added to the sample tube. The emission 
of fluorescence (525 nm) was then immediately recorded 
for 300 s. 
Statistical analysis
Data handling, analyses and graphic representation 
was performed using Microsoft Office Excel 2010. 
Statistical analyses were performed using two tailed 
unpaired Student’s t tests, after having confirmed that 
populations did not display statistically different variances. 
The differences between the mean values were considered 
significant when P < 0.05, where * means P < 0.05, ** 
means P < 0.01 and *** means P < 0.005.
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